Sopharma management commentary says H1 2026 earnings rise on higher sales, boosted by brands acquired in late 2024

PUBT · 1d ago
Sopharma management commentary says H1 2026 earnings rise on higher sales, boosted by brands acquired in late 2024
  • Sopharma management commentary flagged H1 2026 revenue of EUR 717.74 million, up 10.4%, driven by higher product sales.
  • EBITDA rose 37.5% to EUR 74.63 million, reflecting sales growth, with a lift from finished-product brands acquired in late 2024.
  • Operating profit increased 46.3% to EUR 53.47 million; net profit climbed 35.9% to EUR 52.82 million.
  • Other operating income rose to EUR 12.4 million, supported by a EUR 4.3 million gain from the Biopharm Sliven business sale.
  • Working-capital investment weighed on cash, with inventories and receivables rising; normalized free cash flow improved to EUR 2.45 million from EUR -86.27 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sopharma AD published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.